salicylic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
analgesic anti-inflammatory 2416 69-72-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • choline salicylate
  • choline subsalicylate
  • salicylic acid
  • 2-Carboxyphenol
  • 2-Hydroxybenzenecarboxylic acid
  • 2-Hydroxybenzoic acid
  • imidazole salicylate
  • sodium salicylate
  • morpholine salicylate
  • potassium salicylate
A compound obtained from the bark of the white willow and wintergreen leaves. It has bacteriostatic, fungicidal, and keratolytic actions.
  • Molecular weight: 138.12
  • Formula: C7H6O3
  • CLOGP: 2.19
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 57.53
  • ALOGS: -1.09
  • ROTB: 1

Drug dosage:

DoseUnitRoute
3 g O
3 g O
7 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 2.51 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 15 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 100 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.378 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.531 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 47.753 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.567 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 3.040 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 22.220 % High 1
herg hERG pIC50 4.480 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.256 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.221 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 3.550 % High 1
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDPK1,PIK3CB,PIK3CD,PIM1,PIM2,PLK1,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 68
kinase-selectivity-class ACVR2A,ACVR2B,AURKB,AXL,BRAF,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FGFR1,GRK2,GSK3B,JAK2,MAP2K3,MAP2K6,MAP3K14,MAPK1,MAPK12,MAPK7,MAPK8,MARK4,PIK3CD,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK 32
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 2.421 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.396 High 1
mh-clint Mouse hepatocyte intrinsic clearance 4.335 High 1
mppb Mouse plasma protein binding (% unbound) 22.830 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.074 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 1.800 % High 1
rat-kpuu-brain Rat brain Kpuu 0.273 % High 1
rh-clint Rat hepatocyte intrinsic clearance 9.311 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 84.180 % High 1
rppb Rat plasma protein binding (% unbound) 2.530 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 779.830 uM High 1

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1898 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 846.05 17.05 326 21807 37644 90568670
Chronic sinusitis 321.24 17.05 143 21990 23659 90582655
Paraesthesia oral 285.28 17.05 144 21989 31515 90574799
Vaginal flatulence 282.85 17.05 109 22024 12529 90593785
Female genital tract fistula 272.45 17.05 117 22016 17751 90588563
Procedural pain 266.70 17.05 140 21993 33220 90573094
Proctitis 262.95 17.05 109 22024 15150 90591164
Radiculopathy 258.77 17.05 114 22019 18391 90587923
Completed suicide 257.47 17.05 241 21892 144817 90461497
Vaginal discharge 240.58 17.05 110 22023 19354 90586960
Oral candidiasis 175.96 17.05 109 22024 35346 90570968
Colitis ulcerative 146.78 17.05 120 22013 60146 90546168
Frequent bowel movements 139.99 17.05 114 22019 56821 90549493
Seronegative arthritis 130.16 17.05 71 22062 18163 90588151
Joint dislocation 128.40 17.05 98 22035 44484 90561830
Dyspepsia 127.04 17.05 196 21937 197964 90408350
Haematochezia 125.98 17.05 118 22015 70795 90535519
Erythema 124.15 17.05 210 21923 229036 90377278
Joint stiffness 123.79 17.05 122 22011 77920 90528394
Colitis 121.60 17.05 115 22018 69827 90536487
Therapeutic product effect incomplete 119.02 17.05 188 21945 193708 90412606
Rectal haemorrhage 114.21 17.05 120 22013 82624 90523690
Weight decreased 110.83 17.05 269 21864 379641 90226673
Prescribed underdose 98.57 17.05 106 22027 74913 90531401
Osteoporosis 95.82 17.05 118 22015 96413 90509901
Sciatica 78.97 17.05 110 22023 101272 90505042
Walking aid user 76.70 17.05 66 22067 35440 90570874
Retinitis 74.11 17.05 67 22066 38391 90567923
Lupus vulgaris 72.46 17.05 71 22062 44988 90561326
Wound infection 70.57 17.05 107 22026 106295 90500019
Infusion related reaction 68.09 17.05 240 21893 416540 90189774
Upper respiratory tract infection 67.32 17.05 116 22017 128202 90478112
Laryngitis 67.15 17.05 72 22061 50681 90555633
Psoriasis 66.57 17.05 125 22008 147629 90458685
Lupus-like syndrome 65.87 17.05 70 22063 48776 90557538
Broncholithiasis 64.56 17.05 15 22118 292 90606022
Skin burning sensation 62.89 17.05 46 22087 19565 90586749
Joint range of motion decreased 62.66 17.05 116 22017 135527 90470787
Lymph node calcification 60.99 17.05 15 22118 375 90605939
Toxicity to various agents 58.87 17.05 179 21954 287667 90318647
Foot deformity 56.09 17.05 71 22062 59580 90546734
Visual impairment 54.73 17.05 108 22025 132257 90474057
Carbuncle 53.25 17.05 18 22115 1418 90604896
Fatigue 51.77 17.05 130 22003 1153893 89452421
Anti-cyclic citrullinated peptide antibody 51.61 17.05 47 22086 27174 90579140
Suspected suicide 51.50 17.05 31 22102 9537 90596777
Road traffic accident 50.90 17.05 93 22040 107533 90498781
Skin irritation 50.76 17.05 35 22098 13568 90592746
Hypercholesterolaemia 47.48 17.05 87 22046 100805 90505509
Osteoarthritis 46.03 17.05 128 22005 195602 90410712
Type 2 diabetes mellitus 44.95 17.05 130 22003 203114 90403200
Monoclonal immunoglobulin present 42.85 17.05 17 22116 2107 90604207
Hypothalamo-pituitary disorder 41.89 17.05 17 22116 2235 90604079
Spinal fusion surgery 39.81 17.05 29 22104 12254 90594060
Knee arthroplasty 39.48 17.05 72 22061 83110 90523204
Adjustment disorder with depressed mood 38.93 17.05 58 22075 56695 90549619
Spondylitis 38.26 17.05 30 22103 14148 90592166
Dislocation of vertebra 38.11 17.05 57 22076 55911 90550403
Disability 37.52 17.05 48 22085 40697 90565617
Liver function test increased 37.21 17.05 71 22062 84784 90521530
Hepatic cirrhosis 36.91 17.05 60 22073 63193 90543121
Hip arthroplasty 36.21 17.05 66 22067 76142 90530172
Bronchial wall thickening 35.94 17.05 15 22118 2116 90604198
Amyloid arthropathy 35.83 17.05 14 22119 1666 90604648
Exostosis 34.59 17.05 53 22080 53081 90553233
Urticaria 34.12 17.05 159 21974 312575 90293739
Red blood cell sedimentation rate increased 32.46 17.05 66 22067 82529 90523785
Asthma-chronic obstructive pulmonary disease overlap syndrome 32.00 17.05 18 22115 4881 90601433
Bone erosion 31.89 17.05 51 22082 52970 90553344
Asthenia 31.64 17.05 51 22082 533700 90072614
Total lung capacity increased 31.59 17.05 18 22115 5003 90601311
Overweight 31.35 17.05 19 22114 5915 90600399
Lichen nitidus 31.25 17.05 7 22126 115 90606199
Wheezing 30.47 17.05 127 22006 237953 90368361
Maternal exposure during pregnancy 30.34 17.05 26 22107 360037 90246277
Lower limb fracture 29.99 17.05 65 22068 84948 90521366
Contraindicated product administered 29.65 17.05 21 22112 320118 90286196
Pyrexia 29.63 17.05 268 21865 660217 89946097
Exposure via ingestion 29.61 17.05 14 22119 2653 90603661
Prescribed overdose 29.28 17.05 70 22063 97555 90508759
Fall 28.58 17.05 46 22087 481764 90124550
Deep vein thrombosis postoperative 28.32 17.05 57 22076 70752 90535562
Pulmonary fibrosis 27.96 17.05 73 22060 107430 90498884
Nasal polyps 27.17 17.05 22 22111 10858 90595456
Wrist deformity 27.03 17.05 14 22119 3224 90603090
Fibrosis 26.27 17.05 17 22116 5935 90600379
Cough 26.11 17.05 31 22102 368931 90237383
Therapeutic product effect decreased 25.98 17.05 18 22115 277553 90328761
Abdominal pain upper 25.69 17.05 26 22107 332648 90273666
Grip strength decreased 25.24 17.05 64 22069 92512 90513802
Acute kidney injury 24.78 17.05 25 22108 320362 90285952
Dyspnoea 24.71 17.05 121 22012 880834 89725480
Swollen joint count increased 24.43 17.05 71 22062 111135 90495179
Treatment failure 24.34 17.05 23 22110 303905 90302409
Constipation 23.86 17.05 133 22000 280262 90326052
Diarrhoea 23.55 17.05 134 21999 939056 89667258
Ear infection 23.08 17.05 52 22081 69723 90536591
Autoimmune disorder 22.98 17.05 55 22078 76689 90529625
Hypomania 22.24 17.05 18 22115 8879 90597435
Drug interaction 22.04 17.05 21 22112 276432 90329882
Neutropenia 21.83 17.05 14 22119 224890 90381424
Nephropathy 21.65 17.05 18 22115 9217 90597097
Exposure during pregnancy 21.60 17.05 16 22117 238394 90367920
Disease progression 21.16 17.05 6 22127 156609 90449705
Oedema peripheral 21.06 17.05 121 22012 257794 90348520
Product use issue 20.99 17.05 30 22103 329889 90276425
Oedema 20.48 17.05 100 22033 200195 90406119
Jaundice cholestatic 20.34 17.05 18 22115 10025 90596289
Irritable bowel syndrome 20.10 17.05 102 22031 207346 90398968
Product use in unapproved indication 20.02 17.05 32 22101 336204 90270110
Pain of skin 19.84 17.05 22 22111 16060 90590254
Aplastic anaemia 19.65 17.05 20 22113 13249 90593065
Sarcoidosis 19.39 17.05 18 22115 10655 90595659
Psoriatic arthropathy 19.22 17.05 108 22025 228227 90378087
Drug-induced liver injury 19.20 17.05 57 22076 90261 90516053
Chemical burn of skin 18.83 17.05 5 22128 171 90606143
Pulmonary pain 18.71 17.05 13 22120 5101 90601213
Bronchiectasis 18.53 17.05 25 22108 22305 90584009
Dyslipidaemia 18.28 17.05 17 22116 10090 90596224
Urinary tract infection 18.27 17.05 29 22104 305603 90300711
Cerebrovascular accident 18.10 17.05 4 22129 123529 90482785
Somnolence 17.72 17.05 15 22118 209069 90397245
Drug intolerance 17.30 17.05 54 22079 447537 90158777
Dry skin 17.24 17.05 54 22079 88019 90518295
Cholelithiasis 17.22 17.05 39 22094 52467 90553847
Proctalgia 17.21 17.05 15 22118 8183 90598131
Drug hypersensitivity 17.17 17.05 57 22076 463552 90142762
Palpitations 17.11 17.05 6 22127 136722 90469592

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 380.58 21.06 186 4010 96279 42520860
Anal inflammation 137.82 21.06 34 4162 2195 42614944
SARS-CoV-2 test negative 129.82 21.06 31 4165 1744 42615395
Toxicity to various agents 128.81 21.06 134 4062 229002 42388137
Proctalgia 102.85 21.06 35 4161 7058 42610081
Accident 101.83 21.06 34 4162 6469 42610670
Choroiditis 70.20 21.06 18 4178 1357 42615782
Body temperature increased 67.24 21.06 35 4161 20323 42596816
Haemorrhoids 67.00 21.06 33 4163 17064 42600075
Endophthalmitis 56.98 21.06 20 4176 4413 42612726
Skin burning sensation 50.13 21.06 21 4175 7466 42609673
Suspected suicide 43.56 21.06 18 4178 6181 42610958
Intraocular pressure increased 39.60 21.06 17 4179 6416 42610723
Erythema 39.50 21.06 51 4145 108742 42508397
Visual acuity reduced 38.32 21.06 23 4173 17527 42599612
Skin exfoliation 31.96 21.06 29 4167 41524 42575615
Dry skin 31.94 21.06 31 4165 48307 42568832
Eye pain 31.30 21.06 20 4176 17010 42600129
Chondritis 28.40 21.06 6 4190 192 42616947
Condition aggravated 27.15 21.06 71 4125 260683 42356456
Exposure via ingestion 25.09 21.06 9 4187 2113 42615026
Psoriasis 24.56 21.06 27 4169 48577 42568562
Pain of skin 24.13 21.06 13 4183 8067 42609072

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 620.34 14.71 422 17640 241959 110329278
Macular degeneration 404.98 14.71 147 17915 21512 110549725
Chronic sinusitis 362.55 14.71 141 17921 24943 110546294
Vaginal flatulence 326.01 14.71 108 17954 12036 110559201
Female genital tract fistula 323.34 14.71 116 17946 16403 110554834
Paraesthesia oral 322.43 14.71 141 17921 33530 110537707
Procedural pain 305.47 14.71 138 17924 35427 110535810
Radiculopathy 294.74 14.71 113 17949 19223 110552014
Proctitis 290.92 14.71 108 17954 16819 110554418
Vaginal discharge 288.61 14.71 109 17953 17799 110553438
Erythema 198.53 14.71 241 17821 291206 110280031
Oral candidiasis 195.83 14.71 110 17952 44650 110526587
Toxicity to various agents 183.47 14.71 301 17761 480254 110090983
Therapeutic product effect incomplete 163.70 14.71 192 17870 223613 110347624
Colitis ulcerative 160.82 14.71 119 17943 77244 110493993
Frequent bowel movements 157.88 14.71 114 17948 71276 110499961
Rectal haemorrhage 128.52 14.71 126 17936 119707 110451530
Dyspepsia 125.13 14.71 155 17907 190810 110380427
Colitis 123.79 14.71 115 17947 102208 110469029
Haematochezia 119.30 14.71 119 17943 115405 110455832
Skin burning sensation 113.05 14.71 60 18002 21765 110549472
Anal inflammation 112.43 14.71 33 18029 2463 110568774
Proctalgia 106.20 14.71 49 18013 13173 110558064
SARS-CoV-2 test negative 103.77 14.71 30 18032 2123 110569114
Suspected suicide 93.76 14.71 47 18015 15152 110556085
Skin irritation 73.77 14.71 41 18021 16278 110554959
Weight decreased 66.34 14.71 197 17865 467860 110103377
Broncholithiasis 65.60 14.71 14 18048 278 110570959
Infusion related reaction 65.39 14.71 172 17890 380990 110190247
Accident 65.01 14.71 33 18029 10919 110560318
Lymph node calcification 59.00 14.71 14 18048 455 110570782
Carbuncle 55.70 14.71 17 18045 1450 110569787
Exposure via ingestion 55.05 14.71 23 18039 4877 110566360
Dry skin 54.40 14.71 77 17985 107576 110463661
Choroiditis 54.09 14.71 17 18045 1598 110569639
Psoriasis 46.97 14.71 83 17979 139910 110431327
Monoclonal immunoglobulin present 46.55 14.71 17 18045 2523 110568714
Constipation 46.34 14.71 146 17916 357640 110213597
Skin exfoliation 44.73 14.71 63 17999 87588 110483649
Hypothalamo-pituitary disorder 44.66 14.71 17 18045 2829 110568408
Malaise 43.11 14.71 220 17842 671599 109899638
Pain of skin 42.01 14.71 31 18031 19998 110551239
Pyrexia 41.83 14.71 270 17792 897995 109673242
Amyloid arthropathy 41.33 14.71 14 18048 1666 110569571
Total lung capacity increased 41.22 14.71 19 18043 5093 110566144
Asthma-chronic obstructive pulmonary disease overlap syndrome 37.32 14.71 19 18043 6325 110564912
Overweight 36.98 14.71 19 18043 6445 110564792
Nasal polyps 33.62 14.71 23 18039 13177 110558060
Endophthalmitis 32.77 14.71 19 18043 8168 110563069
Wrist deformity 32.61 14.71 14 18048 3175 110568062
Bronchial wall thickening 32.53 14.71 14 18048 3193 110568044
Lichen nitidus 32.52 14.71 7 18055 145 110571092
Fatigue 30.26 14.71 100 17962 1215858 109355379
Sciatica 29.98 14.71 54 18008 92345 110478892
Chemical burn of skin 29.72 14.71 7 18055 220 110571017
Abdominal pain 29.44 14.71 163 17899 512826 110058411
Hypomania 28.90 14.71 19 18043 10191 110561046
Fibrosis 28.65 14.71 17 18045 7625 110563612
Haemorrhoids 28.35 14.71 32 18030 35640 110535597
Soft tissue necrosis 25.66 14.71 9 18053 1189 110570048
Sarcoidosis 25.33 14.71 19 18043 12560 110558677
Body temperature increased 24.53 14.71 37 18025 54676 110516561
Body height decreased 23.63 14.71 17 18045 10546 110560691
Osteoporosis 23.41 14.71 47 18015 87105 110484132
Rhinitis allergic 23.32 14.71 21 18041 17901 110553336
Cholelithiasis 23.09 14.71 39 18023 63383 110507854
Jaundice cholestatic 22.82 14.71 19 18043 14589 110556648
Pulmonary pain 21.02 14.71 13 18049 6280 110564957
Intraocular pressure increased 20.95 14.71 16 18046 10860 110560377
Pain 20.93 14.71 243 17819 954712 109616525
Nephropathy 19.97 14.71 17 18045 13450 110557787
Movement disorder 19.81 14.71 27 18035 36377 110534860
Bone density decreased 19.32 14.71 18 18044 16024 110555213
Anaemia 19.30 14.71 154 17908 546932 110024305
Chondritis 18.91 14.71 5 18057 254 110570983
Dyslipidaemia 17.49 14.71 17 18045 15948 110555289
Renal cyst 17.42 14.71 18 18044 18154 110553083
Therapeutic product effect delayed 16.89 14.71 10 18052 4469 110566768
Joint swelling 16.88 14.71 29 18033 442816 110128421
Bronchiectasis 16.81 14.71 25 18037 36468 110534769
Schizophrenia 16.37 14.71 19 18043 21807 110549430
Aplastic anaemia 16.32 14.71 20 18042 24288 110546949
Dyspnoea 16.27 14.71 110 17952 1106762 109464475
Drug interaction 16.25 14.71 36 18026 500147 110071090
Cardiac murmur 16.11 14.71 20 18042 24608 110546629
Skin swelling 15.81 14.71 12 18050 8068 110563169
Visual acuity reduced 14.77 14.71 22 18040 32151 110539086

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D01AE12 DERMATOLOGICALS
ANTIFUNGALS FOR DERMATOLOGICAL USE
ANTIFUNGALS FOR TOPICAL USE
Other antifungals for topical use
ATC G04BX17 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Other urologicals
ATC N02BA03 NERVOUS SYSTEM
ANALGESICS
OTHER ANALGESICS AND ANTIPYRETICS
Salicylic acid and derivatives
ATC N02BA04 NERVOUS SYSTEM
ANALGESICS
OTHER ANALGESICS AND ANTIPYRETICS
Salicylic acid and derivatives
ATC N02BA08 NERVOUS SYSTEM
ANALGESICS
OTHER ANALGESICS AND ANTIPYRETICS
Salicylic acid and derivatives
ATC N02BA12 NERVOUS SYSTEM
ANALGESICS
OTHER ANALGESICS AND ANTIPYRETICS
Salicylic acid and derivatives
ATC N02BA16 NERVOUS SYSTEM
ANALGESICS
OTHER ANALGESICS AND ANTIPYRETICS
Salicylic acid and derivatives
ATC S01BC08 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFLAMMATORY AGENTS
Antiinflammatory agents, non-steroids
CHEBI has role CHEBI:35480 analgesic
MeSH PA D000700 Analgesics
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D016861 Cyclooxygenase Inhibitors
MeSH PA D018501 Antirheumatic Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D018712 Analgesics, Non-Narcotic
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35718 antifungal agent
CHEBI has role CHEBI:37848 plant hormone
CHEBI has role CHEBI:50176 keratolytic drug
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:50247 antidote
CHEBI has role CHEBI:50249 anticoagulant
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:73181 EC 1.11.1.11 (<small>L</small>-ascorbate peroxidase) inhibitor
CHEBI has role CHEBI:76924 plant metabolite
CHEBI has role CHEBI:84735 algal metabolite
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
MeSH PA D003879 Dermatologic Agents
MeSH PA D007641 Keratolytic Agents

Related Drugs by ATC class:

D01AE Other antifungals for topical use 23 drugs
2-(4-chlorphenoxy)-ethanolamorolfinebromochlorosalicylanilidebutenafinechlorphenesin carbamateciclopiroxdimazoleethyl hydroxybenzoateflucytosinehaloproginliranaftatemethylrosaniline show all 23 →
G04BX Other urologicals 10 drugs
acetohydroxamic aciddapoxetinedimethyl sulfoxidemagnesium hydroxidemethenaminepentosan polysulfatephenazopyridinephenyl salicylatesuccinimidetiopronin
N02BA Salicylic acid and derivatives 11 drugs
acetylsalicylic acidaloxiprinbenorilatecarbasalate calciumdiflunisaldipyrocetylethenzamideguacetisalmagnesium salicylatesalicylamidesalsalate
S01BC Antiinflammatory agents, non-steroids 10 drugs
bendazacbromfenacdiclofenacflurbiprofenindomethacinketorolacnepafenacoxyphenbutazonepiroxicampranoprofen

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Tinea pedis indication 6020002 DOID:12403
Pain indication 22253000
Greasy skin indication 42273000
Seborrheic dermatitis indication 50563003 DOID:8741
Allergic rhinitis indication 61582004
Verruca plantaris indication 63440008 DOID:13775
Rheumatoid arthritis indication 69896004 DOID:7148
Common cold indication 82272006 DOID:10459
Tinea corporis indication 84849002
Acne vulgaris indication 88616000
Pityriasis simplex indication 200767005
Disorder of keratinization indication 277905003
Fever indication 386661006
Hyperkeratosis indication 396228006
Osteoarthritis indication 396275006
Synovitis indication 416209007 DOID:2703
Calluses and Corns indication
Crohn's disease off-label use 34000006
Tendinitis off-label use 34840004 DOID:971
Rheumatic fever off-label use 58718002 DOID:1586
Ulcerative colitis off-label use 64766004 DOID:8577
Tenosynovitis off-label use 67801009 DOID:970
Juvenile rheumatoid arthritis off-label use 410795001
Itching of skin off-label use 418363000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.81 acidic
pKa2 12.79 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Carbonic anhydrase 2 Enzyme Ki 5.15 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 5 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 4.95 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 4.10 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 5.06 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 4.09 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 4.92 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 4.30 CHEMBL
High mobility group protein B1 Nuclear other Kd 6 CHEMBL
Nicotinate phosphoribosyltransferase Enzyme Ki 9.80 CHEMBL
Salicylic acid-binding protein 2 Enzyme WOMBAT-PK
Carbonic anhydrase 13 Enzyme Ki 4.17 CHEMBL
Polyphenol oxidase 2 Enzyme IC50 4 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 5.14 CHEMBL
Solute carrier family 22 member 20 Transporter Ki 4.36 CHEMBL

External reference:

IDSource
4018663 VUID
N0000146974 NUI
D00097 KEGG_DRUG
2016-36-6 SECONDARY_CAS_RN
36364-49-5 SECONDARY_CAS_RN
54-21-7 SECONDARY_CAS_RN
4018419 VANDF
4018434 VANDF
4018663 VANDF
4018996 VANDF
C0036079 UMLSCUI
CHEBI:16914 CHEBI
SAL PDB_CHEM_ID
CHEMBL424 ChEMBL_ID
DB00936 DRUGBANK_ID
CHEMBL2104095 ChEMBL_ID
CHEMBL2104788 ChEMBL_ID
CHEMBL447868 ChEMBL_ID
CHEMBL3707214 ChEMBL_ID
CHEMBL3707342 ChEMBL_ID
D020156 MESH_DESCRIPTOR_UI
338 PUBCHEM_CID
4306 IUPHAR_LIGAND_ID
C015075 MESH_SUPPLEMENTAL_RECORD_UI
147-90-0 SECONDARY_CAS_RN
578-36-9 SECONDARY_CAS_RN
O414PZ4LPZ UNII
DB14006 DRUGBANK_ID
DB13860 DRUGBANK_ID
20974 RXNORM
4438 MMSL
5235 MMSL
5439 MMSL
5494 MMSL
9170 MMSL
d00492 MMSL
d00843 MMSL
001586 NDDF
001590 NDDF
001592 NDDF
001951 NDDF
005692 NDDF
006027 NDDF
370179008 SNOMEDCT_US
387253001 SNOMEDCT_US
387411000 SNOMEDCT_US
46741005 SNOMEDCT_US
65302009 SNOMEDCT_US
72968006 SNOMEDCT_US
D012980 MESH_DESCRIPTOR_UI
1938 INN_ID
5485 INN_ID
O414PZ4LPZ INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SkinMedica Acne Clarifying Treatment HUMAN OTC DRUG LABEL 1 0023-1230 LOTION 20 mg TOPICAL OTC Monograph Drug 11 sections
SKIN MEDICA Purifying Foaming Wash HUMAN OTC DRUG LABEL 1 0023-4948 LIQUID 20 mg TOPICAL OTC Monograph Drug 10 sections
DHS SAL4 oz. HUMAN OTC DRUG LABEL 1 0096-0738 SHAMPOO 0.04 g TOPICAL OTC Monograph Drug 8 sections
DHS SAL4 oz. HUMAN OTC DRUG LABEL 1 0096-0738 SHAMPOO 0.04 g TOPICAL OTC Monograph Drug 8 sections
DHS SAL HUMAN OTC DRUG LABEL 1 0096-0812 SHAMPOO 30 mg TOPICAL OTC Monograph Drug 13 sections
Cetaphil Gentle Clear Mattifying Acne Moisturizer HUMAN OTC DRUG LABEL 1 0299-4117 LOTION 5 mg TOPICAL OTC Monograph Drug 9 sections
Cetaphil Gentle Clear Clarifying Acne Cleanser HUMAN OTC DRUG LABEL 1 0299-4119 CREAM 20 mg TOPICAL OTC Monograph Drug 10 sections
Cetaphil Acne Relief Body Wash HUMAN OTC DRUG LABEL 1 0299-4121 GEL 20 mg TOPICAL OTC Monograph Drug 10 sections
Differin Acne Clearing Body Wash HUMAN OTC DRUG LABEL 1 0299-4131 GEL 20 mg TOPICAL OTC Monograph Drug 11 sections
Differin Acne Clearing Body HUMAN OTC DRUG LABEL 1 0299-4132 AEROSOL, SPRAY 2 g TOPICAL OTC Monograph Drug 11 sections
Cetaphil Gentle Clear Triple-Action Acne Serum HUMAN OTC DRUG LABEL 1 0299-4135 SOLUTION 5 mg TOPICAL OTC Monograph Drug 9 sections
Cetaphil Gentle Clear Pore Clearing Acne Cleanser HUMAN OTC DRUG LABEL 1 0299-4143 GEL 20 mg TOPICAL OTC Monograph Drug 10 sections
Differin Acne Clearing Body Scrub HUMAN OTC DRUG LABEL 1 0299-4609 LIQUID 20 mg TOPICAL OTC Monograph Drug 10 sections
ALMAY CLEAR COMPLEXION CONCEALER HUMAN OTC DRUG LABEL 1 0311-0725 LIQUID 2 mg TOPICAL OTC Monograph Drug 8 sections
ALMAY CLEAR COMPLEXION CONCEALER HUMAN OTC DRUG LABEL 1 0311-0731 LIQUID 2 mg TOPICAL OTC Monograph Drug 8 sections
ALMAY CLEAR COMPLEXION CONCEALER HUMAN OTC DRUG LABEL 1 0311-0732 LIQUID 2 mg TOPICAL OTC Monograph Drug 8 sections
ALMAY CLEAR COMPLEXION CONCEALER HUMAN OTC DRUG LABEL 1 0311-0733 LIQUID 2 mg TOPICAL OTC Monograph Drug 8 sections
ALMAY CLEAR COMPLEXION CONCEALER HUMAN OTC DRUG LABEL 1 0311-0734 LIQUID 2 mg TOPICAL OTC Monograph Drug 8 sections
ALMAY CLEAR COMPLEXION CONCEALER HUMAN OTC DRUG LABEL 1 0311-0735 LIQUID 2 mg TOPICAL OTC Monograph Drug 8 sections
Almay Clear Complexion MakeupBuff HUMAN OTC DRUG LABEL 1 0311-0742 LIQUID 2 mg TOPICAL OTC Monograph Drug 8 sections
Almay Clear Complexion MakeupNaked HUMAN OTC DRUG LABEL 1 0311-0743 LIQUID 2 mg TOPICAL OTC Monograph Drug 8 sections
Almay Clear Complexion MakeupNeutral HUMAN OTC DRUG LABEL 1 0311-0744 LIQUID 2 mg TOPICAL OTC Monograph Drug 8 sections
Almay Clear Complexion MakeupBeige HUMAN OTC DRUG LABEL 1 0311-0745 LIQUID 2 mg TOPICAL OTC Monograph Drug 8 sections
Almay Clear Complexion MakeupSand Beige HUMAN OTC DRUG LABEL 1 0311-0746 LIQUID 2 mg TOPICAL OTC Monograph Drug 8 sections
Almay Clear Complexion MakeupWarm Beige HUMAN OTC DRUG LABEL 1 0311-0747 LIQUID 2 mg TOPICAL OTC Monograph Drug 8 sections
Almay Clear Complexion MakeupIvory HUMAN OTC DRUG LABEL 1 0311-0748 LIQUID 2 mg TOPICAL OTC Monograph Drug 8 sections
ALMAY CLEAR COMPLEXION MAKEUP FOUNDATIONTrue Beige HUMAN OTC DRUG LABEL 1 0311-0754 EMULSION 1 mg TOPICAL OTC Monograph Drug 7 sections
ALMAY CLEAR COMPLEXION MAKEUP FOUNDATIONSun Beige HUMAN OTC DRUG LABEL 1 0311-0755 EMULSION 1 mg TOPICAL OTC Monograph Drug 7 sections
ALMAY CLEAR COMPLEXION MAKEUP FOUNDATIONPorcelain HUMAN OTC DRUG LABEL 1 0311-0756 EMULSION 1 mg TOPICAL OTC Monograph Drug 7 sections
ALMAY CLEAR COMPLEXION MAKEUP FOUNDATIONIvory HUMAN OTC DRUG LABEL 1 0311-0757 EMULSION 1 mg TOPICAL OTC Monograph Drug 7 sections